Identification of HLA-A*0201- and A*2402-restricted epitopes of mucin 5AC expressed in advanced pancreatic cancer

Pancreas

Volumn 40, Issue 6, 2011, Pages 896-904

  Yamazoe, Sadaaki ^a   Tanaka, Hiroaki ^a   Iwauchi, Takehiko ^a   Yoshii, Mami ^a   Ito, Gentaro ^a   Amano, Ryosuke ^a   Yamada, Nobuya ^a   Sawada, Tetsuji ^a   Ohira, Masaichi ^a   Hirakawa, Kosei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CD8 T lymphocytes; immunohistochemistry; immunotherapy; MUC5AC; pancreatic cancer; peptide vaccine

Indexed keywords

CANCER VACCINE; EPITOPE; GAMMA INTERFERON; HLA A ANTIGEN; MUCIN 5AC; HLA A*02:01 ANTIGEN; HLA A*24:02 ANTIGEN; HLA A2 ANTIGEN; HLA A24 ANTIGEN; HLA-A*02:01 ANTIGEN; HLA-A*24:02 ANTIGEN; MESSENGER RNA; MUC5AC PROTEIN, HUMAN; RNA;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURGERY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSTIMULATION; INTERFERON PRODUCTION; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; LYMPHOCYTE CLONE; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN TARGETING; TARGET CELL; AMINO ACID SEQUENCE; BIOSYNTHESIS; CHEMISTRY; FEMALE; GENETICS; IMMUNOLOGY; IN VITRO STUDY; METABOLISM; MIDDLE AGED; PANCREAS CARCINOMA; PANCREAS TUMOR; TUMOR CELL LINE;

AGED; AMINO ACID SEQUENCE; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; EPITOPES, T-LYMPHOCYTE; FEMALE; HLA-A2 ANTIGEN; HLA-A24 ANTIGEN; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-GAMMA; MALE; MIDDLE AGED; MUCIN 5AC; PANCREATIC NEOPLASMS; RNA, MESSENGER; RNA, NEOPLASM; T-LYMPHOCYTES, CYTOTOXIC;

EID: 80051544713     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31821ad8d1     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71-96. (Pubitemid 351521864)
2. Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: A report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg. 1999;189(1):1-7. (Pubitemid 29307735)
3. Benson AB 3rd. Adjuvant therapy for pancreatic cancer: One small step forward. JAMA. 2007;297(3):311-313. (Pubitemid 46143311)
4. Lockhart AC, Rothenberg ML, Berlin JD. Treatment for pancreatic cancer: Current therapy and continued progress. Gastroenterology. 2005;128(6):1642-1654. (Pubitemid 40692557)
5. Boon T. Tumor antigens recognized by cytolytic T lymphocytes: Present perspectives for specific immunotherapy. Int J Cancer. 1993;54(2):177Y180.
6. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med. 1996;183(3):725-729. (Pubitemid 26113944)
7. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254(5038):1643-1647. (Pubitemid 21917508)
8. Brichard V, Van Pel A, Wolfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1993;178(2):489-495. (Pubitemid 23218197)
9. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2Yrestricted tumor infiltrating lymphocytes. J Exp Med. 1994;180(1):347Y352.
10. Laheru D, Jaffee EM. Immunotherapy for pancreatic cancerVscience driving clinical progress. Nat Rev Cancer. 2005;5(6):459-467. (Pubitemid 40791488)
11. Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988; 53(4):549-554.
12. Ohuchida K, Mizumoto K, Yamada D, et al. Quantitative analysis of MUC1 and MUC5AC mRNA in pancreatic juice for preoperative diagnosis of pancreatic cancer. Int J Cancer. 2006;118(2):405-411. (Pubitemid 41779080)
13. Toubaji A, Achtar M, Provenzano M, et al. Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunol Immunother. 2008;57(9): 1413-1420.
14. Lepisto AJ, Moser AJ, Zeh H, et al. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther. 2008;6(B):955-964.
15. Gjertsen MK, Buanes T, Rosseland AR, et al. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer. 2001;92(3):441-450. (Pubitemid 32249724)
16. Kondo H, Hazama S, Kawaoka T, et al. Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes. Anticancer Res. 2008;28(1B):379-387. (Pubitemid 351362841)
17. Kanno A, Satoh K, Kimura K, et al. The expression of MUC4 and MUC5AC is related to the biologic malignancy of intraductal papillary mucinous neoplasms of the pancreas. Pancreas. 2006;33(4):391-396. (Pubitemid 44690730)
18. Kim GE, Bae HI, Park HU, et al. Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas. Gastroenterology. 2002;123(4):1052-1060.
19. Takikita M, Altekruse S, Lynch CF, et al. Associations between selected biomarkers and prognosis in a population-based pancreatic cancer tissue microarray. Cancer Res. 2009;69(7):2950-2955.
20. Han L, Pansare V, Al-Abbadi M, et al. Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology. Diagn Cytopathol. 2010;38(5):333-336.
21. Kuzushima K, Hayashi N, Kimura H, et al. Efficient identification of HLA-A*2402Yrestricted cytomegalovirus-specific CD8(+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. Blood. 2001;98(6):1872-1881.
22. Yamazoe S, Tanaka H, Sawada T, et al. RNA interference suppression of mucin 5AC (MUC5AC) reduces the adhesive and invasive capacity of human pancreatic cancer cells. J Exp Clin Cancer Res. 2010;29:53.
23. Kato S, Hokari R, Crawley S, et al. MUC5AC mucin gene regulation in pancreatic cancer cells. Int J Oncol. 2006;29(1):33-40.
24. Tsai V, Southwood S, Sidney J, et al. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J Immunol. 1997;158(4):1796-1802. (Pubitemid 127469536)
25. Wang Y, Gao J, Li Z, et al. Diagnostic value of mucins (MUC1, MUC2 and MUC5AC) expression profile in endoscopic ultrasound-guided fine-needle aspiration specimens of the pancreas. Int J Cancer. 2007;121(12):2716-2722. (Pubitemid 350136417)
26. Nagata K, Horinouchi M, Saitou M, et al. Mucin expression profile in pancreatic cancer and the precursor lesions. J Hepatobiliary Pancreat Surg. 2007;14(3):243-254. (Pubitemid 46863913)
27. Yonezawa S, Higashi M, Yamada N, et al. Significance of mucin expression in pancreatobiliary neoplasms. J Hepatobiliary Pancreat Surg. 2010;17(2):108-124.
28. Rong Y, Jin D, Wu W, et al. Induction of protective and therapeutic antiYpancreatic cancer immunity using a reconstructed MUC1 DNA vaccine. BMC Cancer. 2009;9:191.
29. Mukherjee P, Pathangey LB, Bradley JB, et al. MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model. Vaccine. 2007;25(9):1607Y1618.
30. Ramanathan RK, Lee KM, McKolanis J, et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother. 2005;54(3):254-264. (Pubitemid 40174243)
31. Loveland BE, Zhao A, White S, et al. Mannan-MUC1Ypulsed dendritic cell immunotherapy: A phase I trial in patients with adenocarcinoma. Clin Cancer Res. 2006;12(3 Pt 1):869-877. (Pubitemid 43259870)
32. Apostolopoulos V, Pietersz GA, Tsibanis A, et al. Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res. 2006;8(3):R27.
33. Pecher G, Haring A, Kaiser L, et al. Mucin gene (MUC1) transfected dendritic cells as vaccine: Results of a phase I/II clinical trial. Cancer Immunol Immunother. 2002;51(11-12):669-673. (Pubitemid 35446294)
34. Hollingsworth MA, Swanson BJ. Mucins in cancer: Protection and control of the cell surface. Nat Rev Cancer. 2004;4(1):45-60. (Pubitemid 38082153)
35. Yokokawa J, Palena C, Arlen P, et al. Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. Clin Cancer Res. 2005;11(17):6342-6351. (Pubitemid 41262966)
36. Li M, Bharadwaj U, Zhang R, et al. Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther. 2008;7(2):286-296. (Pubitemid 351302523)
37. Browning M, Krausa P. Genetic diversity of HLA-A2: Evolutionary and functional significance. Immunol Today. 1996;17(4):165-170. (Pubitemid 26113084)
38. Date Y, Kimura A, Kato H, et al. DNA typing of the HLA-A gene: Population study and identification of four new alleles in Japanese. Tissue Antigens. 1996;47(2):93-101. (Pubitemid 26067938)
39. Watanabe T, Suda T, Tsunoda T, et al. Identification of immunoglobulin superfamily 11 (IGSF11) as a novel target for cancer immunotherapy of gastrointestinal and hepatocellular carcinomas. Cancer Sci. 2005;96(8):498-506. (Pubitemid 41387302)
40. Imai K, Hirata S, Irie A, et al. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers. Clin Cancer Res. 2008;14(20):6487Y6495.
41. Suda T, Tsunoda T, Uchida N, et al. Identification of secernin 1 as a novel immunotherapy target for gastric cancer using the expression profiles of cDNA microarray. Cancer Sci. 2006;97(5):411-419.
42. Nukaya I, Yasumoto M, Iwasaki T, et al. Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. Int J Cancer. 1999;80(1):92-97. (Pubitemid 28559783)